PW Medtech Group Ltd. ( (HK:1358) ) has issued an announcement.
PW Medtech Group Limited announced the audited financial results of its non-wholly owned subsidiary, Sichuan Ruijian Medical, for the nine months ending September 30, 2024. The subsidiary reported a revenue of RMB 341,698,000 and a profit of RMB 92,279,000, with total assets amounting to RMB 888,759,000. These results, prepared in accordance with China Accounting Standards, will be consolidated into PW Medtech’s accounts after adjustments. This announcement highlights the subsidiary’s strong financial performance, which may positively impact the group’s market positioning and investor relations.
More about PW Medtech Group Ltd.
PW Medtech Group Limited is an investment holding company incorporated in the Cayman Islands. The group is primarily involved in the research, development, manufacturing, and sales of advanced infusion sets, intravenous cannula products, insulin needles, blood purification medical devices, as well as animal-derived regenerative medical biomaterial and human tissue repair products in China.
YTD Price Performance: -10.91%
Average Trading Volume: 3,294
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €172.8M
Find detailed analytics on 1358 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com